June 13, 2012:Sanaria and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant
September 8, 2011: Science publishes Sanaria's Research Article, Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity
June 29, 2011: Sanaria announces the launch of its Sanaria®Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology
February 23, 2010: Sanaria Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research grant to develop a genetically attenuated whole parasite malaria vaccine
February 19, 2010: Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria's PfSPZ vaccine
September 16, 2009: Sanaria receives multi-year U.S. NIH phase II Small Business Innovation Research grant to enhance efficiency and scale-up of its malaria vaccine manufacturing process
June 2, 2009: Sanaria receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
April 23, 2009: Sanaria and PATH-MVI announce that Phase 1 trial of Sanaria's whole-parasite malaria vaccine called PfSPZ Vaccine to begin; FDA approval for testing in humans watershed moment for unique malaria vaccine approach
October 30, 2008: Sanaria and TI Pharma collaborators at Radboud University Nijmegen Medical Centre and Leiden University Medical Centre publish the first report of genetically attenuated P. falciparum sporozoites
July 29, 2008: Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant
May 15, 2008: Sanaria named Maryland's Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration
January 16, 2008: Sanaria, Top Institute Pharma, Radboud University Nijmegen Medical Centre and Leiden University Medical Center enter into $23.6 million research agreement
October 26, 2007: Sanaria, PATH Malaria Vaccine Initiative Open Manufacturing Facility For Producing World's First "Whole-Parasite" Malaria Vaccine
January 29, 2007: Sanaria Inc. Receives Multi-Year $3.47 Million U.S. NIH Phase I and Phase II Small Business Innovation Research Grants to Enhance Development of its Malaria Vaccine
December 14, 2006: PATH Malaria Vaccine Initiative Announces New Partnership To Accelerate Development of Novel Malaria Vaccine Candidate MVI and Sanaria Inc. to Conduct Initial Safety and Test-of-Concept Trial
March 19, 2006: Sanaria CEO, Dr. Stephen L. Hoffman, is the most cited author in the world
June 20, 2005: Sanaria Receives NIAID (NIH) award for Development of its Malaria Vaccine
May 2, 2005: Sanaria Receives U.S. Army Award for Development of its Malaria Vaccine
October 20, 2004: Dr. Stephen L. Hoffman Elected to Membership in the Institute of Medicine of National Academies
July 13, 2004: The Institute for One World Health and Sanaria
March 2013 - Sanaria's CEO & CSO, Dr. Stephen L. Hoffman, ranked 21st out of the 50 most influential people in vaccines; 50 most influential
January 2013 - In collaboration with the Radboud University Nijmegen Medical Center, a high level of controlled human malaria infection (CHMI) was achieved with Sanaria® PfSPZ Challenge paving the way towards the elimination of the need for live mosquito bites to test anti-malarial vaccines and drugs; AJTMH, Healio
June 2012 - Sanaria and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant
January 2012 - The Sanaria®PfSPZ Vaccine is being assessed in a clinical trial at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
March 2011 - Sanaria is proud to announce the appointment of Peter F. Billingsley, PhD, Senior Director of Entomology and Quality Systems, to the Editorial Board of the Malaria Journal; more information
December 2010 - Sanaria, in collaboration with the Walter Reed Army Institute of Research and the Center for Disease Control/National Center for Infectious Disease, publish research results in PLoS ONE; Establishment of an In Vitro Assay for Assessing the Effects of Drugs on the Liver Stages of Plasmodium vivax Malaria
October 2010 - Sanaria, in collaboration with the University of Maryland School of Medicine and Protein Potential, LLC, publish clinical trial results in PLoS ONE; Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial
September 2010 - Sanaria honored to be ranked 15th among all Maryland businesses in The Gazette of Politics and Business Exceptional 53 Business Awards; P & B 53
August 2010 - Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Mental Floss
magazine article, The Quest for a Malaria Vaccine and the Man Who Risked Everything to Find It; mentalfloss.com
August 2010 - Sanaria's Chief Executive and Scientific Officer, Dr. Stephen L. Hoffman won the Daily Record's Innovator of the Year Award; The Daily Record
August 2010 - Sanaria recognized by U.S. Representative Chris Van Hollen for using Recovery Act funding to retain employees and continue its focus on developing a malaria vaccine; POLITICO
January 2010 - Dr. David Dolberg, Sanaria's Director of Intellectual Property, is recognized for his contributions to paradigm changing research in cancer; more information
September 2009 - Sanaria ranked 22nd in The Gazette of Politics and Business Exceptional 53 Business Award; Announcement
September 2009: Sanaria receives multi-year U.S. NIH phase II Small Business Innovation Research grant to enhance efficiency and scale-up of its malaria vaccine manufacturing process; Press Release
July 2009: Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in U.S. News and World Report article, Why a Man Let 2,000 Malaria-Infected Mosquitoes Bite Him; usnews.com
June 2009: Sanaria featured in Associated Press article, Pulling malaria from mosquitoes to fight disease
April 2009: Sanaria and PATH-MVI announce that Phase 1 trial of Sanaria's whole-parasite malaria vaccine called PfSPZ Vaccine to begin; FDA approval for testing in humans watershed moment for unique malaria vaccine approach; Press Release
April 2009: Sanaria wins VIE Award for Best Early-Stage Vaccine Biotech at the World Vaccine Congress Washington; ViE; Press Release
December 2008: Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Esquire magazine
July 2008: Sanaria and TI Pharma collaborators publish the first report of genetically attenuated Pf sporozoites; PLoS ONE; Press Release
July 2008 Sanaria and the Univ of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant Press Release
May 2008: Sanaria named Emerging Company of the Year at the TCM's Tech Awards; TCM; Press Release; Gazette.net
November 2007: Sanaria announced that Adel A. F. Mahmoud, M.D., Ph.D, of the Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University and former President of Merck Vaccines, was elected to Sanaria's Board of Directors
October 2007: Sanaria opens Clinical Manufacturing Facility; Press Release: featured in Reuters
October 2007: Fred Binka (Sanaria Advisory Board Member) featured in Newsweek,"Giving Globally: The Search for Solutions"
July 2007: Sanaria featured in National Geographic magazine, Bedlam in the Blood, Malaria
